Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 28, 2017
Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinomaAlexander Solms, Isabel Reinecke, Sabine Fiala-Buskies, et al.
BMC Medical Research Methodology|August 5, 2022
Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare settingRong Chen, Dmitry Gultyaev, Johanna Lister, et al.
Annals of Hematology|September 25, 2020
Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia AAlexander Solms, Anita Shah, Erik Berntorp, et al.
Annals of Hematology|June 26, 2019
Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia AAnita Shah, Alexander Solms, Sara Wiegmann, et al.
European Journal of Haematology|April 8, 2020
BAY 81-8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS studyCristina Santoro, Beng Fuh, Phu Quoc Le, et al.
Clinical and Translational Science|April 2, 2024
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteersTianxing Liu, Kensei Hashizume, Eva Krieg, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 19, 2024
Population pharmacokinetic-pharmacodynamic model of elinzanetant based on integrated clinical phase I and II dataStefan Willmann, Adam Lloyd, Rupert Austin, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 6, 2019
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic SamplingAlexander Solms, Matthias Frede, Scott D Berkowitz, et al.
Clinical Pharmacology and Therapeutics|February 21, 2023
Opportunities and Challenges of Disease Progression Modeling in Drug Development - An IQ PerspectiveKosalaram Goteti, Nathan Hanan, Mindy Magee, et al.
The Cochrane Database of Systematic Reviews|July 8, 2011
Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shockSusanne Unverzagt, Maria-Theresia Machemer, Alexander Solms, et al.
Pageof 3